<DOC>
	<DOCNO>NCT03093870</DOCNO>
	<brief_summary>This protocol Varlitinib develop treatment Biliary Tract Cancer . Varlitinib ( also know ASLAN001 ) small-molecule , adenosine triphosphate competitive inhibitor tyrosine kinases - epidermal growth factor receptor ( EGFR ) , human epidermal growth factor receptor ( HER ) 2 , HER4 . Varlitinib may beneficial subject cancer simultaneous inhibition receptor . The purpose study determine safety efficacy Varlitinib combination capecitabine treatment Biliary Tract Cancer . Treatment group Varlitinib+capecitabine Placebo + capecitabine</brief_summary>
	<brief_title>Varlitinib Combination With Capecitabine Advanced Metastatic Biliary Tract Cancer</brief_title>
	<detailed_description />
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Subjects eligible study : 1 . Are old legal age respective country time write informed consent obtain 2 . Have histologically cytologically confirm advanced ( unresectable ) metastatic biliary tract cancer , include intrahepatic extrahepatic CCA , gallbladder cancer carcinoma Ampulla Vater 3 . Have receive fail one one prior line systemic treatment advance metastatic disease clear evidence disease progression . This prior line systemic treatment must also contain gemcitabine . 4 . Have radiographically measurable disease base RECIST v1.1 5 . Have evidence biliary duct obstruction , unless obstruction control local treatment , biliary tree decompress endoscopic percutaneous stenting subsequent reduction bilirubin 1.5 x upper level normal ( ULN ) 6 . Have Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 7 . Have estimate life expectancy 3 month 8 . Are able understand willing sign inform consent form 9 . Have adequate organ hematological function : 1 . Hematological function , follow : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelet count ≥ 100 x 109/L 2 . Renal function , follow : eGFR CrCl &gt; 60 mL/min/1.73m2 3 . Hepatic function , follow : Total bilirubin ≤ 1.5 x ULN Aspartate aminotransferase alanine aminotransferase ≤ 5 x ULN Subjects ineligible study : 1 . Are currently receive anticancer therapy within past 4 week 2 . Are currently receive radiation local treatment within past 4 week target lesion ( ) 3 . Have major surgical procedure within 14 day prior study entry 4 . Have metastatic brain lesion ( ) , include asymptomatic well control lesion ( ) 5 . Have malabsorption syndrome , diseases significantly affect gastrointestinal function , resection stomach small bowel , difficulty swallow retain oral medication 6 . Have uncontrolled intercurrent illness include , limited , ongoing active infection , unstable angina pectoris , cardiac arrhythmia , diabetes , hypertension , psychiatric illness/social situation would limit compliance study requirement 7 . Have history malignancy unless remission 1 year ( nonmelanoma skin carcinoma carcinomainsite uterine cervix treat curative intent exclusionary ) 8 . Are female subject pregnant breast feed 9 . Have previously treat varlitinib capecitabine 10 . Have receive investigational drug ( use investigational device ) within last 14 day receive first dose study medication 11 . Have unresolved unstable serious toxicity ( ≥ CTCAE 4.03 Grade 2 ) prior administration another investigational drug and/or prior cancer treatment 12 . Have know positive test human immunodeficiency virus , active hepatitis C , hepatitis B infection hepatitis B virus DNA exceed 2000 IU/mL 13 . Have know history drug addiction within last 1 year 14 . Need continuous treatment proton pump inhibitor study period 15 . Have history ( noninfectious ) pneumonitis require steroid current pneumonitis , history interstitial lung disease current interstitial lung disease 16 . Have history presence clinically significant cardiovascular , respiratory , hepatic , renal , hematologic , gastrointestinal , endocrine , immunologic , dermatologic , neurologic psychiatric disease condition opinion Investigator could jeopardize safety subject validity study result . Have baseline QTcF &gt; 450ms . And safety leadin : subject know long QT syndrome , family history sudden death , torsade de pointes , symptomatic ventricular tachycardia , unstable cardiac syndrome past 3 month screen visit , &gt; class 2 NYHA heart failure , &gt; class 2 angina pectoris .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Biliary Tract Neoplasms</keyword>
	<keyword>Bile Duct Neoplasms</keyword>
	<keyword>Gallbladder Neoplasms</keyword>
</DOC>